Publication | Closed Access

IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group

Hematological MalignancyLymphoid NeoplasiaPhase-ii StudyMedicineImmunologyHematologyImmune Checkpoint InhibitorImmunotherapyOncologyRadiation OncologyAnti-cd20 Antibody TreatmentHealth Sciences